The present study evaluates the effects of Nasal CPAP on serum levels of High-mobility group protein 1 (HMGB1) in obstructive sleep apnea syndrome (OSAS).
Fifteen healthy subjects and 20 subjects with moderately severe or severe OSAS who desired nasal CPAP treatment were prospectively enrolled. Serum levels of HMGB1 and the plasma level of NOx from peripheral blood samples were measured, and all subjects underwent a sleep study. These studies were repeated 2 months after Nasal CPAP treatment in the patients with OSAS.
The results showed that for healthy subjects, there was no difference in serum level of HMGB1 and NOx between baseline and 2 months later. The serum level of HMGB1 was higher than in normal subjects but the plasma level of NOx was lower when compared with normal subjects. The serum levels of NOx in patients with OSAS increased from 16.9 ± 6.2 to 30.8 ± 6.5 αM after nasal CPAP treatment. HMGB1 decreased from 7.8 ± 2.8 to 4.2 ± 2.0 ng/mL after nasal CPAP treatment.
In conclusion, increased serum level of HMGB1 and reduced plasma NOx in patients with OSAS returns to normal after Nasal CPAP treatment.
NOx and HMGB1 may be used as markers for determining the effectiveness of OSAS treatment.
Ching-Chi Lin, No Financial Disclosure Information; No Product/Research Disclosure Information